Abstract Biallelic inactivation of ATM gene causes the rare autosomal recessive disorder Ataxia-telangiectasia (A-T). Female relatives of A-T patients have a two-fold higher risk of developing breast cancer (BC) compared with the general population. ATM mutation carrier identification is laborious and expensive, therefore, a more rapid and directed strategy for ATM mutation profiling is needed. We designed a case-control study to determine the prevalence of 32 known ATM mutations causing A-T in Spanish population in 323 BRCA1/BRCA2 negative hereditary breast cancer (HBC) cases and 625 matched Spanish controls. For the detection of the 32 ATM mutations we used the matrix-assisted laser desorption/ionization time-of-flight mass spectrometry technique. We identified one patient carrier of the c.8264_8268delATAAG ATM mutation. This mutation was not found in the 625 controls. These results suggest a low frequency of these 32 A-T causing mutations in the HBC cases in our population. Further case-control studies analyzing the entire coding and flanking sequences of the ATM gene are warranted in Spanish BC patients to know its implication in BC predisposition.
Introduction
Breast cancer (BC) is the most frequently diagnosed cancer among western women. Approximately 7% of BC cases are of hereditary origin [1] . To date, several BC susceptibility alleles have been identified and categorized into three groups according to their population frequency and the risks conferred: rare high-penetrance alleles, moderate-penetrance alleles, and common low-penetrance alleles [2] . The BRCA1 and BRCA2 genes are the two major predisposition highpenetrance genes to BC conferring a risk that is 10-30 times the risk among women in the general population. However, germline mutations in these genes only account for up to 16% of the hereditary breast cancer (HBC) burden [3] . Mutations in other BC predisposing high-penetrance genes such as TP53, STK11, CDH1, PTEN, and lately RAD51C [4] are also associated with HBC, but each one has a small contribution to familial BC (1%) except for the patients with specific features or in the context of rare cancer syndromes [5, 6] . Recently published genome-wide association studies provide evidence for low-penetrant BC susceptibility loci that confer a small relative risk up to 1.5-fold and an overall 8% of the HBC risk [7] . A third group known as moderate-penetrance BC genes confers increased risks of two to fourfold compared to the 10% risk in the general population. Thus far, five moderate-risk BC genes have been convincingly identified: CHEK2, BRIP1, PALB2, NBS1, and ATM [8] .
The ATM gene (ataxia telangiectasia mutated; MIM#60 7585) encodes a lipid kinase phosphatidylinositol 3-kinase (PI3K) expressed in a wide range of tissues. It is the key player of a signaling cascade that detects and repairs DNA double-strand breaks, a cascade in which the BRCA1 and BRCA2 proteins are involved [9] . Biallelic inactivation of ATM gene causes the rare autosomal recessive disorder Ataxia-telangiectasia (A-T), a neurodegenerative disorder characterised by progressive cerebellar ataxia and dysarthria, associated with ocular telangiectasia, immunodeficiency, sensitivity to ionising radiation, and an increased risk of cancers, especially leukemias and lymphomas [10] . Most of the patients with A-T are compound heterozygotes (inheriting distinct ATM mutations from each parent) and over 70% of these mutations are base substitutions, small insertions or deletions and splicing alterations that generate premature termination codons which in turn result in a truncated and unstable ATM protein (see http://chromium. liacs.nl/LOVD2/home.php?select_db=ATM) [11] . The prevalence of such ATM mutations has been shown to be as high as 0.5-1% in Western general populations [12] . The link between A-T and BC arouse from clinical and epidemiological studies observing that female relatives of A-T patients had an increased risk of BC [12] [13] [14] [15] . This association was definitively confirmed in a case-control study by Renwick et al. [16] . The authors analyzed 443 cases of familial BC and 521 controls, and found 12 women carrying an ATM mutation in the case group (2.70%) and two in the control group (0.38%). They estimated that ATM mutation heterozygosity was associated with a BC relative risk (RR) of 2.37 (95% CI: 1.51-3.78). Our group [17] reported the first results of ATM germline mutations in Spanish population with early-onset BC and showed that one of 43 patients (2.3%) had a deleterious truncating ATM mutation (c.3802delG) that causes A-T in the homozygous state.
Despite all this evidence, the large size of ATM (it contains 63 exons spanning approximately 150 kb of genomic DNA) and its very heterogeneous mutational spectrum makes mutation carrier identification laborious and expensive. Hence a rapid and more directed strategy for ATM mutation profiling is needed. Founder effects for ATM mutations have been reported in different countries, including Spain [18] [19] [20] . All the 13 ATM mutations identified by Renwick et al. [16] were predicted to cause A-T, and nine of those identified in cases have previously been reported in A-T families, including the two most common mutations in the UK, c.5762ins137 and c.3802delG. More recently, a study of Bogdanova et al. [21] provided evidence for the association of an ATM founder mutation (c.5932G[T; p.E1978X, a common A-T causing mutation) with BC in Eastern European populations. These findings suggest that it is possible to approach carrier testing by first identifying the most common mutations in selected populations and then developing rapid assays that use small amounts of genomic DNA and less costly methods.
The goal of our study was to confirm the implication of ATM as a susceptibility gene in BRCA1/BRCA2 wild-type HBC Spanish families. We designed a case-control Spanish HBC study to determine the prevalence of known ATM mutations causing A-T in Spanish populations using the matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) technique.
Patients and methods

Patient samples
Genomic DNA was available from index cases of 323 BRCA1 and BRCA2 wild-type Spanish HBC families from two distinct populations of Spanish origin: Catalonian and Galician. The 228 Catalonian cases were selected from high risk families with at least three cases of BC among relatives of 1st and 2nd degree and no cases of ovarian cancer or male BC. The families were recruited from the cancer genetics clinics of the Catalan Institute of Oncology, University Hospital Vall d'Hebron, and Santa Creu i Sant Pau Hospital from Barcelona, Catalan Institute of Oncology of Girona and Sant Joan University Hospital of Tarragona. The 95 Galician HBC cases had previously been studied by Blanco et al. [22] for germline mutations in TP53 and PTEN. All participants provided written informed consent and the study was approved by the institutional review boards. DNA samples from up to 625 geographically matched Caucasian Spanish controls (426 from Catalonia and 199 from Galicia) without personal or familial antecedents of any cancer were also analyzed to establish the frequency of the 32 selected mutations in each respective population. DNA was quantified using NanoDrop 1000 spectrophotometer (Thermo Scientific, Wilmington, USA) and diluted to a final concentration of 20 ng/ll for genotyping.
ATM mutation selection
We analyzed 32 ATM mutations responsible for A-T in Spanish population previously described by Mitui M. et al. [18] , Castellví-Bel et al. [20] , and García Pérez et al. [23] , together with the ATM mutation and the likely deleterious variants reported previously by our group in early-onset BC Spanish patients negative for BRCA1/2 mutations [17] (Table 1) .
Genotyping
Mutation screening of the 32 mutations was performed at the Spanish National Genotyping Center in the node of Santiago de Compostela by MALDI-TOF MS using the Sequenom MassArray System and iPLEX Gold genotyping chemistry. The design of oligonucleotides was carried out according to the guidelines of Sequenom and performed using MassAR-RAY Assay Design software (version 1.0). Mutations detected were confirmed by bi-directional sequencing with ''Big Dye Terminator v3.1 Cycles Sequencing kit'' (Applied Byosistems, Warrington, UK) on ABI PRISM 3730xl Genetic Analyzer (Applied Biosystems) in accordance with the manufacturer's instructions. Primer sequences are available on request. Sequences were examined using Staden Package software (Open Source Technology Group, Inc.).
Results and discussion
In this study, we analyzed the presence of 32 ATM mutations in BRCA1/BRCA2 negative Spanish HBC samples using MALDI-TOF mass spectrometry technology. The genotyped mutations were selected since were known to be responsible for A-T in Spanish populations.
We identified the mutation c.8264_8268delATAAG in heterozygous state in a Catalonian woman with BC at the age of 34 (Fig. 1a, b) . The patient had two first degree relatives diagnosed with BC at the ages of 58 and 66, but none sample was available from these patients. The mutation was confirmed by direct sequencing (Fig. 1c) . No other mutations were found in control or case samples. Interestingly, c.8264_8268delATAAG had previously been identified in one Spanish, one Costa Rican, and three Brazilian A-T patients with different STRs and SNPs haplotypes, suggesting that these represent independent mutational events or a hot-spot in the ATM gene [18] .
The utility of genetic testing of BC genes has comprehensively been shown for BRCA1 and BRCA2 genes [24] . The demonstration that ATM mutations predispose to BC [16] could also be used in risk stratification of women to allow them to make changes on their medical surveillance and lifestyle habits to reduce their risk of BC. Nevertheless, it is not yet known what determines which women with ATM mutations will develop BC (around 15% of female ATM carriers) [25] and this limits the clinical utility of identifying such mutations. Moreover, the significance of most ATM missense variants is unknown and only a few of them have been considered to be pathogenic. Recently, Fletcher et al. [26] showed that the combined effects of five missense ATM SNPs were associated with a small increased risk of BC, explaining an estimated 0.03% of the excess familial risk of BC. Tavtigian et al. [27] used an in silico missense-substitution analysis to assess the contribution to BC risk of rare ATM variants described in seven published ATM case-control studies and from their own mutation screening data of additional case-control analyses. They provided evidence that a subset of rare missense ATM substitutions confer increased BC risk. An analysis on a subset of these rare variants lead them to propose the hypothesis that the missense mutations conferring increased risk of BC are more concentrated in the last third of the ATM protein (FAT, kinase, and FATC domains) and that a subset of these missense substitutions actually confer higher risk of BC than do protein-truncating variants on average. Moreover, if ATM mutations act multiplicatively with other genetic BC factors it may be possible to identify women with combinations of BC susceptibility alleles, which all together give risks similar to those of BRCA1/2.
The ATM mutation status may also be of relevance for the treatment of BC due to its influence on response to radiation, as it has recently been suggested in a nested case-control study within a cohort of 52,536 survivors of unilateral BC. Women who carried deleterious ATM variants and who were treated with radiation had a statistically significantly higher risk of contralateral BC [28] .
Together, these data reveal that ATM truncating variants, as well as a number of missense variants confer BC risk. However, their prevalence is usually low and their variety may differ widely among populations from different geographical or ethnic origins. Therefore, taking the complexity and size of the gene into account, specific analysis approaches are necessary by using reliable, flexible, and rapid methodologies.
Several methods have previously been used to screen for ATM mutations to overcome the complexity of analyzing ATM gene, such as a non-isotopic RNase cleavage-based assay (NIRCA) [29] , denaturating gradient gel electrophoresis (DGGE) [30] , single-strand conformational polymorphism (SSCP) [31] , denaturing high-performance liquid chromatography (DHPLC) [32] , and more recently enhanced mismatch mutation analysis (EMMA) [33] . Despite the availability of all these techniques for ATM analysis, Sanger sequencing of the entire coding and flanking sequences of ATM gene remains standard making ATM mutation identification expensive and labor intensive.
We analyzed in BRCA1/BRCA2 negative Spanish HBC samples a panel of 32 ATM mutations previously found in A-T Spanish patients using MALDI-TOF mass spectrometry. In our hands, this methodology was technically successful to study this set of ATM selected mutations. Nevertheless, the predictive power of our approach is low Future steps in moderate-risk BC genes mutation profiling, such as ATM, will probably require a comprehensive strategy by full sequencing of the genome applying massive parallel ''next generation'' sequencing procedures. Preliminary reports [34] suggest that this sequencing technology would enable accurate and cost-effective full screening of a large number of predisposition genes involved in HBC.
